Zhejiang Ausun Pharmaceutical Co Ltd - Asset Resilience Ratio
Zhejiang Ausun Pharmaceutical Co Ltd (603229) has an Asset Resilience Ratio of 0.12% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Zhejiang Ausun Pharmaceutical Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Zhejiang Ausun Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 603229 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Ausun Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603229 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥3.87 Million | 0.12% |
| Total Liquid Assets | CN¥3.87 Million | 0.12% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Ausun Pharmaceutical Co Ltd maintains only 0.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Ausun Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Ausun Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Zhejiang Ausun Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Ausun Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.13% | CN¥3.94 Million ≈ $575.96K |
CN¥3.09 Billion ≈ $451.47 Million |
+0.05pp |
| 2024-12-31 | 0.08% | CN¥2.24 Million ≈ $328.16K |
CN¥2.98 Billion ≈ $436.42 Million |
-0.10pp |
| 2022-12-31 | 0.17% | CN¥4.02 Million ≈ $588.13K |
CN¥2.32 Billion ≈ $338.81 Million |
-5.81pp |
| 2021-12-31 | 5.98% | CN¥110.00 Million ≈ $16.10 Million |
CN¥1.84 Billion ≈ $269.17 Million |
+5.92pp |
| 2019-12-31 | 0.06% | CN¥542.46K ≈ $79.38K |
CN¥886.14 Million ≈ $129.67 Million |
-0.05pp |
| 2018-12-31 | 0.11% | CN¥857.79K ≈ $125.52K |
CN¥801.98 Million ≈ $117.35 Million |
-0.06pp |
| 2016-12-31 | 0.16% | CN¥734.11K ≈ $107.42K |
CN¥446.06 Million ≈ $65.27 Million |
-- |
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more